



Antibody-Based Imaging and Targeted Therapy in Cancer

Guest Editor:

Prof. Dr. Hirofumi Hanaoka

Department of
Radiotheranostics, Gunma
University Graduate School of
Medicine, 3-39-22 Showa-machi,
Maebashi 371-8511, Japan

Deadline for manuscript
submissions:

10 October 2024

Message from the Guest Editor

Antibody-based drugs have shown great potential for cancer imaging and therapy since monoclonal antibodies (mAbs) can selectively deliver substances, such as a radionuclide, dyes, and a toxic molecule to the target. Molecular imaging combines imaging agents with mAbs to specifically image diseased sites in the body. For cancer treatment, cytotoxic payload is conjugated to mAbs to selectively deliver the toxic molecule to cancer cells. Radiolabeled antibody and antibody–drug conjugates (ADCs) consisting of a toxic molecule conjugated to a mAb have been developed and used in clinical practice. Recently, antibody-photoactivating chemical conjugates have been developed as a drug for photoimmunotherapy (PIT). PIT targeting EGFR was approved for clinical use in Japan in 2020.

This Special Issue welcomes research articles and review papers focused on the broad area of development of antibody-based drugs. Research areas may include (but are not limited to) the following: development of new drugs for antibody-based cancer imaging, radioimmunotherapy, ADC, photoimmunotherapy, and novel strategies to improve the therapeutic and/or side effect.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com